Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
To own Kenvue, you have to believe its portfolio of everyday health and personal care brands can convert modest revenue growth into improving earnings, despite recent margin pressure and balance sheet leverage. The Texas restraining order raises legal and operational questions, but unless it persists or broadens beyond Texas, it does not appear to alter the near term focus on execution, cost control and stabilizing sales.
The most relevant recent data point is Kenvue’s reaffirmed 2025 outlook for low single digit net and organic sales declines, which already reflects a period of softer category demand and internal transition. Against that backdrop, the Texas registration dispute adds another layer of execution risk at a time when management is trying to simplify a complex global footprint and restore investor confidence.
Yet against that relatively contained picture, investors should be aware that Kenvue’s operational complexity and emerging legal exposure could...
Read the full narrative on Kenvue (it's free!)
Kenvue's narrative projects $16.3 billion revenue and $2.1 billion earnings by 2028.
Uncover how Kenvue's forecasts yield a $19.33 fair value, a 12% upside to its current price.
Five Simply Wall St Community fair value estimates cluster between US$18 and about US$28.85, showing how far apart individual views on Kenvue can be. You are weighing those opinions against a business facing both execution risk in simplifying its brand and geographic footprint and fresh legal uncertainty in Texas, so it often pays to consider several contrasting perspectives before forming your own view.
Explore 5 other fair value estimates on Kenvue - why the stock might be worth just $18.00!
Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com